Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA
Sleep Medicine · 2023
DOI: 10.1016/j.sleep.2023.04.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sleep Medicine, 2023. Verfasst von Mohammad Badran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Child Health Research Institute, Department of Child Health, School of Medicine, University of Missouri, Columbia, MO, USA. Hauptthemen laut MEDLINE: Disorders of Excessive Somnolence, Sleep Apnea, Obstructive. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Jazz Pharmaceuticals Inc Ewing, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND: Obstructive sleep apnea (OSA) is a chronic condition characterized by intermittent hypoxia (IH). Excessive daytime sleepiness (EDS) is a common consequence of OSA and is associated with cognitive deficits and anxiety. Modafinil (MOD) and Solriamfetol (SOL) are potent wake-promoting agents clinically used to improve wakefulness in OSA patients with EDS. METHODS: Male C57Bl/6J mice were exposed to either IH or room air (RA) controls during the light phase for 16 weeks. Both groups were then randomly assigned to receive once-daily intraperitoneal injections of SOL (200 mg/kg), MOD (200 mg/kg) or vehicle (VEH) for 9 days while continuing IH exposures. Sleep/wake activity was assessed during the dark (active) phase. Novel object recognition (NOR), elevated-plus maze test (EPMT), and forced swim test (FST) were performed before and after drug treatment. RESULTS: IH exposure increased dark phase sleep percentage and reduced wake bouts lengths and induced cognitive deficits and anxiogenic effects. Both SOL and MOD treatments decreased sleep propensity under IH conditions, but only SOL promoted improvements in NOR performance (explicit memory) and reduced anxiety-like behaviors. CONCLUSION: Chronic IH, a hallmark feature of OSA, induces EDS in young adult mice that is ameliorated by both SOL and MOD. SOL, but not MOD, significantly improves IH-induced cognitive deficits and promotes anxiolytic effects. Thus, SOL could potentially benefit OSA patients beyond EDS management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Child Health Research Institute, Department of Child Health, School of Medicine, University of Missouri, Columbia, MO, USA.
- Undergraduate Student Research Program, University of Missouri, Columbia, MO, USA.
- Child Health Research Institute, Department of Child Health, School of Medicine, University of Missouri, Columbia, MO, USA; Department of Medical Pharmacology and Physiology, School of Medicine, University of Missouri,…
Förderung
- NIA NIH HHS
- Jazz Pharmaceuticals Inc Ewing
- National Institutes of Health
- University of Missouri
- Jazz Pharmaceuticals
Zitieren
APA
Badran, M., Puech, C., Barrow, M. B., Runion, A. R., & Gozal, D. (2023). Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA. Sleep Medicine. https://doi.org/10.1016/j.sleep.2023.04.007
Vancouver
Badran M, Puech C, Barrow MB, Runion AR, Gozal D. Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA. Sleep Medicine. 2023. doi:10.1016/j.sleep.2023.04.007
BibTeX
@article{Badran2023,
author = {Badran, Mohammad and Puech, Clementine and Barrow, Max B and Runion, Alexandra R and Gozal, David},
title = {Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA},
journal = {Sleep Medicine},
year = {2023},
doi = {10.1016/j.sleep.2023.04.007}
}
EUVIMED